Mabion SA (MAB) AI Stock Analysis

• Market Cap: zł133.18M
• Dividend Yield: N/A
• Average Volume (3M): 38.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: -74.16%
• EPS Growth: -192.42%
• Country: PL
• Employees: 206
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 16,162,327
• 10 Day Avg. Volume: 25,807
• 30 Day Avg. Volume: 38,648
• PEG Ratio: 0.20
• Price to Book (P/B): 1.29
• Price to Sales (P/S): 2.08
• P/FCF Ratio: 5.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: zł8.50 ▲(6.25% Upside)

Mabion SA's overall stock score is primarily impacted by its weak financial performance and technical analysis. The company's declining revenue and negative profitability are significant concerns. Technical indicators suggest bearish momentum, and the negative P/E ratio indicates poor valuation. Improvements in cash flow are a positive aspect but are overshadowed by broader financial challenges.

Mabion SA Business Overview & Revenue Model

Company Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

How the Company Makes Money

Mabion generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company earns money by selling its biosimilars to healthcare providers and pharmaceutical companies, often under licensing agreements that may include upfront payments and royalties based on sales. Additionally, Mabion may engage in partnerships with larger pharmaceutical firms for the co-development and distribution of its products, which can provide significant financial backing and shared resources. The company also benefits from research grants and funding aimed at advancing its innovative drug development pipeline.

Mabion SA Financial Statement Overview

Summary

Mabion SA faces challenges in revenue growth and profitability, with declining revenue and negative net income. The balance sheet is strong with low leverage, but the negative return on equity is a concern. Cash flow improvements are a positive sign, but profitability issues need addressing for sustainable growth.

Income Statement

Mabion SA's income statement reveals a significant decline in revenue by 37.7% in 2024, following a previous decline in 2023. The company has struggled with profitability, evidenced by a negative net profit margin of -9.18% and a negative EBIT margin. However, the EBITDA margin remains positive at 14.78%, indicating some operational efficiency. The gross profit margin has decreased from 75.54% in 2023 to 59.62% in 2024, reflecting challenges in maintaining cost efficiency.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.03 in 2024, indicating low financial leverage. However, the return on equity is negative at -5.68%, reflecting the company's inability to generate profits from its equity base. The equity ratio stands at 69.88%, suggesting a solid capital structure with a high proportion of assets financed by equity.

Cash Flow

Mabion SA's cash flow statement highlights a significant improvement in free cash flow growth by 81.13% in 2024, indicating better cash generation capabilities. The operating cash flow to net income ratio is close to 1, suggesting that the company is effectively converting its net income into cash. However, the free cash flow to net income ratio of 0.68 indicates that not all net income is translating into free cash flow, which could be a concern for future investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.81M	69.02M	151.68M	163.98M	56.87M	0.00
Gross Profit	-26.45M	41.15M	114.58M	65.99M	28.18M	-9.83M
EBITDA	-45.33M	10.20M	58.31M	29.63M	118.00K	-44.27M
Net Income	-59.30M	-6.33M	41.27M	23.19M	1.90M	-57.19M
Balance Sheet
Total Assets	120.46M	159.47M	208.25M	186.18M	184.24M	78.32M
Cash, Cash Equivalents and Short-Term Investments	4.61M	38.45M	47.82M	53.64M	48.71M	2.40M
Total Debt	2.92M	4.61M	35.83M	7.28M	20.36M	36.68M
Total Liabilities	43.86M	48.03M	90.48M	109.67M	130.92M	155.71M
Stockholders Equity	70.02M	111.44M	117.78M	76.51M	53.31M	-77.39M
Cash Flow
Free Cash Flow	-41.46M	26.28M	-40.33M	22.11M	-64.53M	-38.60M
Operating Cash Flow	-40.50M	39.86M	-2.33M	38.84M	-32.91M	-35.24M
Investing Cash Flow	-783.00K	-12.29M	-37.98M	-16.06M	-31.28M	-3.00M
Financing Cash Flow	-1.16M	-36.95M	34.49M	-17.84M	110.50M	12.67M

Mabion SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:MAB, the sentiment is Positive. The current price of 8 is above the 20-day moving average (MA) of 7.25, above the 50-day MA of 7.51, and below the 200-day MA of 8.99, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 72.53 is Negative, neither overbought nor oversold. The STOCH value of 96.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:MAB.

Mabion SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAB	46 Neutral	zł133.18M	-2.25	-59.73%	―	-74.16%	-192.42%
CTX	44 Neutral	zł464.41M	-11.37	-109.96%	―	-40.45%	27.53%
RVU	38 Underperform	zł639.27M	-5.39	-95.69%	―	15.45%	-25.81%